In this issue:
Tumour-restricted delivery of immune-activating molecules by specialised CAR-Ts
Risk factors for severe infections after CAR T-cell therapy in R/R B-ALL
Anti-CD7 allogeneic WU-CART-007 in R/R T-ALL/LBL
Safety profile of CAR-T cell therapy in SLE vs. B-NHL
ZUMA-8: brexucabtagene autoleucel in R/R CLL
T-ICAHT: post-CAR-T thrombocytopenia-based grading & prognostication
CAR transgene levels in tisagenlecleucel-treated R/R B-ALL & DLBCL
Prophylactic tocilizumab before CAR T-cell therapy in older lymphoma patients
Outpatient administration of axicabtagene ciloleucel in R/R DLBCL
Bendamustine vs. fludarabine/ cyclophosphamide lymphodepleting chemotherapy in NHL
Please login below to download this issue (PDF)